Report Highlights

India Radiopharmaceuticals: Market Overview

India's radiopharmaceuticals market represents one of the fastest-growing segments within the country's pharmaceutical industry, valued at USD 312.4 million in 2024. The market encompasses diagnostic radiopharmaceuticals used in nuclear medicine imaging procedures and therapeutic radiopharmaceuticals for targeted cancer treatment. Government policy has fundamentally shaped market development through the Atomic Energy Act 1962 and subsequent amendments, which established the Atomic Energy Regulatory Board (AERB) as the sole licensing authority for radioactive materials. The Department of Atomic Energy's strategic control over nuclear technology has created a unique regulatory environment where private sector participation requires extensive government approval processes.

Market structure reflects this regulatory framework, with public sector undertakings like Board of Radiation and Isotope Technology (BRIT) maintaining significant market share alongside emerging private players. The government's Make in India initiative has specifically targeted radiopharmaceuticals as a priority sector, leading to increased domestic production capabilities. Private sector growth has accelerated following the 2015 amendment to the Atomic Energy Act, which permitted limited private participation in radioactive isotope production. Currently, diagnostic radiopharmaceuticals account for approximately 75% of market value, driven by growing nuclear medicine procedures in oncology and cardiology departments across India's expanding healthcare infrastructure.

Policy-Driven Growth in the radiopharmaceuticals market

The Pradhan Mantri Jan Arogya Yojana (PM-JAY) has emerged as a primary demand driver, covering nuclear medicine procedures under its comprehensive healthcare package for over 500 million beneficiaries. The scheme's inclusion of PET-CT scans and targeted radiotherapy treatments has directly increased radiopharmaceutical consumption, particularly in tier-2 and tier-3 cities where private healthcare access was previously limited. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) allocates INR 1,200 crore annually for cancer treatment infrastructure, with specific provisions for nuclear medicine departments requiring radiopharmaceutical procurement. This policy mechanism translates government healthcare spending into sustained market demand through institutional purchases by government hospitals and empanelled private facilities.

The Production Linked Incentive (PLI) scheme for pharmaceuticals includes a dedicated allocation of INR 500 crore for radiopharmaceutical manufacturing, offering 20% incentives on incremental sales for companies establishing domestic production facilities. The Drug Controller General of India's fast-track approval process, implemented through the New Drugs and Clinical Trials Rules 2019, has reduced radiopharmaceutical registration timelines from 18 months to 8 months for priority products. Additionally, the Central Government Health Scheme (CGHS) now mandates coverage for radiopharmaceutical-based treatments, creating a guaranteed demand base of 3.7 million government employees and their families, with reimbursement rates set at 100% for approved nuclear medicine procedures.

Regulatory Barriers and Compliance Costs

The Atomic Energy Regulatory Board (AERB) imposes stringent licensing requirements that create significant market entry barriers, with radiopharmaceutical manufacturing licenses requiring 24-month approval processes and compliance costs exceeding INR 15 crore for facility establishment. Companies must obtain separate licenses for radioactive material procurement, processing, storage, and distribution, each involving detailed safety assessments and infrastructure inspections. The AERB's Guidelines for Import and Export of Radioactive Sources (2019) mandate 120-day advance approval for isotope imports, creating inventory planning challenges and increasing working capital requirements. Environmental clearance from the Ministry of Environment, Forest and Climate Change adds another 180-day approval timeline, with mandatory environmental impact assessments costing INR 2-3 crore for medium-scale facilities.

The Central Drugs Standard Control Organisation (CDSCO) requires separate drug manufacturing licenses for radiopharmaceutical formulations, involving Good Manufacturing Practice (GMP) certifications that cost INR 5-8 crore for compliance infrastructure. Quality control testing mandates include radiation safety protocols that require specialized equipment and trained personnel, increasing operational costs by 25-30% compared to conventional pharmaceuticals. The Drug Price Control Order (DPCO) 2013 has classified certain radiopharmaceuticals under price control, limiting profit margins to 12-15% for essential nuclear medicine products. Transport regulations under the Atomic Energy (Safe Transport of Radioactive Materials) Rules 2012 require specialized vehicles and trained drivers, adding INR 8-12 lakh monthly logistics costs for nationwide distribution networks.

Policy-Created Opportunities in India

The National Mission on Interdisciplinary Cyber-Physical Systems (NM-ICPS) has allocated INR 3,660 crore for advanced healthcare technology development, with specific provisions for indigenous radiopharmaceutical research and production capabilities. The mission's Technology Innovation Hubs (TIH) program offers 80% funding for radiopharmaceutical R&D projects, creating opportunities for companies developing novel targeted therapy products. The government's announcement of 50 new medical colleges by 2030, each requiring nuclear medicine departments, guarantees institutional demand growth worth an estimated INR 850 crore in radiopharmaceutical procurement. The Indian Space Research Organisation's (ISRO) commercial isotope production program through its upcoming nuclear reactors will provide cost-effective raw materials, reducing import dependence and improving profit margins for domestic manufacturers.

The Ministry of Health and Family Welfare's National Cancer Grid initiative connects 200+ cancer centers nationwide, creating a unified procurement platform that offers volume-based pricing advantages for radiopharmaceutical suppliers. The Foreign Direct Investment (FDI) policy amendment allowing 100% FDI in medical devices through the automatic route now includes certain radiopharmaceutical equipment, facilitating technology transfer partnerships. The Ayushman Bharat Digital Health Mission's integration of nuclear medicine procedures into digital health records creates opportunities for companion diagnostic radiopharmaceuticals tied to personalized medicine protocols. State government initiatives, particularly Kerala's biotechnology policy offering 25% capital subsidy for radiopharmaceutical manufacturing facilities, provide additional localized opportunities for market expansion and cost optimization.

Market at a Glance

Leading Market Participants

• Jubilant Pharma Limited
• Board of Radiation and Isotope Technology (BRIT)
• Piramal Pharma Limited
• GE Healthcare India
• Curium India Private Limited
• Advanced Cyclotron Systems Inc.
• Eckert & Ziegler India
• NTP Radioisotopes SOC Limited
• Cardinal Health India
• Lantheus Medical Imaging India

Regulatory and Policy Environment

The Atomic Energy Act 1962, as amended in 2015, serves as the primary legislative framework governing India's radiopharmaceutical sector, with the Atomic Energy Regulatory Board (AERB) exercising comprehensive oversight authority over all aspects of radioactive material handling and processing. The act mandates that all radiopharmaceutical activities require specific licenses from AERB, including separate authorizations for manufacturing, storage, transportation, and clinical use. The Department of Atomic Energy retains strategic control through the Nuclear Power Corporation of India Limited (NPCIL) and BRIT, which maintains monopoly status for certain isotope production activities. Compliance requirements include radiation safety officer certification, quarterly safety audits, and mandatory insurance coverage of INR 50 crore for manufacturing facilities. The Drug Controller General of India (DCGI) provides parallel oversight for pharmaceutical aspects under the Drugs and Cosmetics Act 1940, creating a dual regulatory structure that requires companies to maintain compliance with both atomic energy and pharmaceutical regulations simultaneously.

Expected regulatory changes include the proposed National Medical Devices Policy 2025, which will classify radiopharmaceuticals as high-risk medical devices requiring enhanced quality systems and post-market surveillance protocols. The AERB is developing new guidelines for radiopharmaceutical clinical trials, expected implementation by 2026, which will align Indian standards with International Atomic Energy Agency (IAEA) recommendations. Compared to regional peers, India's regulatory framework is more restrictive than Singapore's streamlined nuclear medicine approvals but less complex than China's dual-agency oversight system. The upcoming Atomic Energy (Amendment) Bill 2024 proposes to expand private sector participation while maintaining government control over strategic nuclear materials, potentially reducing licensing timelines from 24 months to 12 months for qualified manufacturers and creating a more competitive market environment for non-strategic radiopharmaceutical products.

Long-Term Policy Outlook for India radiopharmaceuticals

The government's National Health Policy 2030 targets establishment of nuclear medicine facilities in all district hospitals, requiring an estimated 400 new departments that will drive radiopharmaceutical demand growth exceeding 20% annually through 2032. The Department of Atomic Energy's strategic plan includes construction of 10 new research reactors by 2030, specifically designed for medical isotope production, which will reduce India's current 70% import dependence to 30% by 2032. The proposed National Radiopharmaceutical Mission, with an allocation of INR 2,500 crore, aims to establish India as a regional hub for isotope production and radiopharmaceutical exports to Southeast Asia and Middle East markets. Integration with the PM Gatishakti infrastructure program will create dedicated logistics corridors for radioactive material transport, reducing distribution costs and improving supply chain reliability.

Policy convergence between the Make in India initiative and the National Mission on Interdisciplinary Cyber-Physical Systems is expected to generate INR 5,000 crore in government-backed research funding for next-generation radiopharmaceutical development by 2030. The anticipated Unified Health Interface under Ayushman Bharat Digital Health Mission will standardize radiopharmaceutical procurement across public healthcare systems, creating a single platform worth an estimated INR 1,200 crore annually in centralized purchases. State-level policies, particularly from pharmaceutical manufacturing hubs like Hyderabad and Ahmedabad, are expected to offer additional incentives for radiopharmaceutical clusters, including dedicated isotope handling infrastructure and specialized training institutes. These policy developments collectively position India's radiopharmaceutical market for sustained double-digit growth, with the regulatory environment evolving from restrictive oversight to facilitative governance that balances safety requirements with commercial viability and innovation encouragement.